NASDAQ : TBPH

Theravance Biopharma, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 17.03 USD (At close: Sep 23, 2026) · Market cap 884.18M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Details

NameTheravance Biopharma, Inc.
SectorHealthcare
IndustryBiotechnology
Employees90
Founded2013
CeoRick Winningham
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinKYG8807B1068
CusipG8807B106
Cik0001583107
Sic2834

Key executives

NameTitle
Rick E. Winningham M.B.A.Chief Executive Officer and Director
Rhonda F. FarnumChief Business Officer and Senior Vice President of Commercial and Medical Affairs
Dr. Aine Miller Ph.D.Senior Vice President of Development and Head of Ireland Office
Aziz Sawaf C.F.A.Senior Vice President of Operations Strategy and Chief Financial Officer
Stuart KnightSenior Vice President of IT&I and Chief Information Officer
Brett A. Grimaud Esq.Senior Vice President, General Counsel and Secretary
Stacy L. PryceSenior Vice President and Chief Strategy Officer

Contact

Address901 Gateway Boulevard, South San Francisco, California 94080, United States
Phone650 808 6000
Websitehttps://www.theravance.com